Grant of Options

RNS Number : 2308A

MaxCyte, Inc.

10 September 2018

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that on 18 July 2018, a total of 550,300 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs
Doerfler, Doug	296,000
Holtz, Ron	134,800
Thompson, J. Stark	23,900
Mandell, Art	23,900
Erck, Stan	23,900
Brooke, Will	23,900
Johnston, John	23,900
Total	550,300

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 18 July 2018, of 243 pence.

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.   For more information, visit http://www.maxcyte.com/

 ###

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer [phone] Nominated Adviser and Broker Panmure Gordon Emma Earl, Freddy Crossley (Corporate Finance) James Stearns (Corporate Broking) [phone] Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Lindsey Neville [phone] [e-mail]

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Names	Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John
2	Reason for the notification
a)	Position/status	Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock
b)	Identification code	US57777K1060
c)	Nature of the transactions	Grant of Options to PDMRs
d)	Price(s) and volume(s)	Doerfler, Doug - 296,000 at an exercise price of 243pence Holtz, Ron - 134,800 at an exercise price of 243 pence Thompson, J. Stark - 23,900 at an exercise price of 243 pence Mandell, Art - 23,900 at an exercise price of 243 pence Erck, Stan - 23,900 at an exercise price of 243 pence Brooke, Will - 23,900 at an exercise price of 243 pence Johnston, John - 23,900 at an exercise price of 243 pence
d)	Aggregated information  - Aggregated volume - Price	n/a
e)	Date of the transactions	18 July 2018
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHEANNNEEAPEFF